vs
Alkermes plc.（ALKS）与Rubrik, Inc.（RBRK）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是Rubrik, Inc.的1.1倍（$384.5M vs $350.2M），Alkermes plc.净利率更高（12.8% vs -18.2%，领先31.1%），Rubrik, Inc.同比增速更快（48.3% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $80.7M）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Rubrik是总部位于美国加利福尼亚州帕洛阿尔托的云数据管理与数据安全企业，成立于2014年1月，专注于为客户提供云环境下的数据管理、安全防护相关解决方案，2024年4月在纽约证券交易所上市。
ALKS vs RBRK — 直观对比
营收规模更大
ALKS
是对方的1.1倍
$350.2M
营收增速更快
RBRK
高出58.8%
-10.6%
净利率更高
ALKS
高出31.1%
-18.2%
自由现金流更多
ALKS
多$89.3M
$80.7M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $350.2M |
| 净利润 | $49.3M | $-63.8M |
| 毛利率 | 88.0% | 80.5% |
| 营业利润率 | 15.1% | -21.6% |
| 净利率 | 12.8% | -18.2% |
| 营收同比 | -10.6% | 48.3% |
| 净利润同比 | -66.3% | 51.2% |
| 每股收益（稀释后） | $0.29 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRBRK
| Q4 25 | $384.5M | $350.2M | ||
| Q3 25 | $394.2M | $309.9M | ||
| Q2 25 | $390.7M | $278.5M | ||
| Q1 25 | $306.5M | $258.1M | ||
| Q4 24 | $430.0M | $236.2M | ||
| Q3 24 | $378.1M | $205.0M | ||
| Q2 24 | $399.1M | $187.3M | ||
| Q1 24 | $350.4M | — |
净利润ALKSRBRK
| Q4 25 | $49.3M | $-63.8M | ||
| Q3 25 | $82.8M | $-95.9M | ||
| Q2 25 | $87.1M | $-102.1M | ||
| Q1 25 | $22.5M | $-114.9M | ||
| Q4 24 | $146.5M | $-130.9M | ||
| Q3 24 | $92.4M | $-176.9M | ||
| Q2 24 | $91.4M | $-732.1M | ||
| Q1 24 | $36.8M | — |
毛利率ALKSRBRK
| Q4 25 | 88.0% | 80.5% | ||
| Q3 25 | 86.9% | 79.5% | ||
| Q2 25 | 87.3% | 78.3% | ||
| Q1 25 | 83.9% | 77.4% | ||
| Q4 24 | 85.6% | 76.2% | ||
| Q3 24 | 83.3% | 73.1% | ||
| Q2 24 | 84.6% | 48.8% | ||
| Q1 24 | 83.3% | — |
营业利润率ALKSRBRK
| Q4 25 | 15.1% | -21.6% | ||
| Q3 25 | 22.6% | -30.5% | ||
| Q2 25 | 23.8% | -33.4% | ||
| Q1 25 | 4.5% | -45.0% | ||
| Q4 24 | 37.8% | -52.8% | ||
| Q3 24 | 27.7% | -82.1% | ||
| Q2 24 | 27.5% | -387.0% | ||
| Q1 24 | 12.4% | — |
净利率ALKSRBRK
| Q4 25 | 12.8% | -18.2% | ||
| Q3 25 | 21.0% | -31.0% | ||
| Q2 25 | 22.3% | -36.7% | ||
| Q1 25 | 7.3% | -44.5% | ||
| Q4 24 | 34.1% | -55.4% | ||
| Q3 24 | 24.4% | -86.3% | ||
| Q2 24 | 22.9% | -390.8% | ||
| Q1 24 | 10.5% | — |
每股收益（稀释后）ALKSRBRK
| Q4 25 | $0.29 | $-0.32 | ||
| Q3 25 | $0.49 | $-0.49 | ||
| Q2 25 | $0.52 | $-0.53 | ||
| Q1 25 | $0.13 | $5.69 | ||
| Q4 24 | $0.88 | $-0.71 | ||
| Q3 24 | $0.55 | $-0.98 | ||
| Q2 24 | $0.53 | $-11.48 | ||
| Q1 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $307.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $-524.4M |
| 总资产 | $2.5B | $2.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSRBRK
| Q4 25 | $388.6M | $307.1M | ||
| Q3 25 | $616.4M | $322.7M | ||
| Q2 25 | $521.2M | $284.0M | ||
| Q1 25 | $399.8M | $186.3M | ||
| Q4 24 | $291.1M | $103.9M | ||
| Q3 24 | $396.3M | $142.3M | ||
| Q2 24 | $535.1M | $502.6M | ||
| Q1 24 | $420.8M | — |
股东权益ALKSRBRK
| Q4 25 | $1.8B | $-524.4M | ||
| Q3 25 | $1.7B | $-564.3M | ||
| Q2 25 | $1.6B | $-556.5M | ||
| Q1 25 | $1.5B | $-553.7M | ||
| Q4 24 | $1.5B | $-521.1M | ||
| Q3 24 | $1.3B | $-499.3M | ||
| Q2 24 | $1.3B | $-514.6M | ||
| Q1 24 | $1.3B | — |
总资产ALKSRBRK
| Q4 25 | $2.5B | $2.5B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.3B | $1.5B | ||
| Q1 25 | $2.1B | $1.4B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $2.2B | $1.2B | ||
| Q1 24 | $2.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $85.5M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $80.7M |
| 自由现金流率自由现金流/营收 | 44.2% | 23.1% |
| 资本支出强度资本支出/营收 | 0.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 3.45× | — |
| 过去12个月自由现金流最近4个季度 | $480.3M | $256.8M |
8季度趋势，按日历期对齐
经营现金流ALKSRBRK
| Q4 25 | $170.1M | $85.5M | ||
| Q3 25 | $101.7M | $64.7M | ||
| Q2 25 | $150.2M | $39.7M | ||
| Q1 25 | $98.8M | $83.6M | ||
| Q4 24 | $190.4M | $23.1M | ||
| Q3 24 | $81.6M | $-27.1M | ||
| Q2 24 | $146.0M | $-31.4M | ||
| Q1 24 | $21.1M | — |
自由现金流ALKSRBRK
| Q4 25 | $170.0M | $80.7M | ||
| Q3 25 | $84.4M | $61.2M | ||
| Q2 25 | $137.2M | $36.8M | ||
| Q1 25 | $88.7M | $78.0M | ||
| Q4 24 | $180.6M | $18.0M | ||
| Q3 24 | $73.3M | $-29.7M | ||
| Q2 24 | $138.9M | $-35.0M | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSRBRK
| Q4 25 | 44.2% | 23.1% | ||
| Q3 25 | 21.4% | 19.8% | ||
| Q2 25 | 35.1% | 13.2% | ||
| Q1 25 | 28.9% | 30.2% | ||
| Q4 24 | 42.0% | 7.6% | ||
| Q3 24 | 19.4% | -14.5% | ||
| Q2 24 | 34.8% | -18.7% | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSRBRK
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 4.4% | 1.1% | ||
| Q2 25 | 3.3% | 1.0% | ||
| Q1 25 | 3.3% | 2.2% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 1.8% | 1.9% | ||
| Q1 24 | 2.4% | — |
现金转化率ALKSRBRK
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RBRK
| Subscription And Circulation | $336.4M | 96% |
| Other | $12.3M | 4% |
| Software And Services | $4.9M | 1% |
| Maintenance | $1.5M | 0% |
